2024
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review
Patel A, Laine L, Moayyedi P, Wu J. AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review. Gastroenterology 2024, 167: 1228-1238. PMID: 39269391, DOI: 10.1053/j.gastro.2024.06.038.Peer-Reviewed Original ResearchPotassium-competitive acid blockerClinical Practice UpdateFirst-line therapyProton pump inhibitorsTwice-daily proton pump inhibitorBest Practice Advice statementsPractice advice statementsPeptic ulcer diseaseErosive esophagitisHeartburn symptomsAmerican Gastroenterological Association (AGA) Institute Clinical Practice UpdateClinical superiorityDouble-dose PPIsDouble-dose proton pump inhibitorsProphylaxis of peptic ulcer diseaseReflux diseaseStandard-dose PPIUlcer diseaseExpert reviewStandard procedures of GastroenterologyHigh-risk stigmataAcid inhibitionOn-demand therapyMaintenance of healingBleeding gastroduodenal ulcers
2023
Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020
Li D, Laine L, Shung D. Trends in Upper Gastrointestinal Bleeding in Patients on Primary Prevention Aspirin: A Nationwide Emergency Department Sample Analysis, 2016-2020. The American Journal Of Medicine 2023, 136: 1179-1186.e1. PMID: 37696350, PMCID: PMC10841721, DOI: 10.1016/j.amjmed.2023.08.010.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal bleedingGastrointestinal bleedingRed blood cell transfusionNationwide Emergency Department SamplePrimary cardiovascular preventionRecent guideline recommendationsBlood cell transfusionProportion of hospitalizationsEmergency Department SampleMedicare reimbursementInternational Statistical ClassificationRelated Health ProblemsCardiovascular preventionCell transfusionOlder patientsHospital admissionCommon etiologyGuideline recommendationsMajor complicationsUlcer diseaseEndoscopic interventionRevision codesAppropriate indicationsRecent guidelinesCardiovascular disease
2018
Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials
Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanas A, Patrono C, Baigent C. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. The Lancet Gastroenterology & Hepatology 2018, 3: 231-241. PMID: 29475806, PMCID: PMC5842491, DOI: 10.1016/s2468-1253(18)30037-2.Peer-Reviewed Original ResearchConceptsProton pump inhibitorsUpper gastrointestinal bleedingPeptic ulcer diseaseAcute upper gastrointestinal bleedingGastrointestinal bleedingUlcer diseasePrevention trialsHealing trialsBlood transfusionClinical circumstancesProstaglandin analoguesHistamine-2 receptor antagonistsParticular proton pump inhibitorsNon-steroidal anti-inflammatory drugsEndoscopic ulcer healingDifferent clinical circumstancesUK Medical Research CouncilBritish Heart FoundationDifferent clinical settingsAnti-inflammatory drugsSmall study biasFurther endoscopic interventionMedical Research CouncilLarge protective effectEndoscopic ulcers
2014
Low Adherence to Helicobacter pylori Testing in Hospitalized Patients with Bleeding Peptic Ulcer Disease
Kim JJ, Lee JS, Olafsson S, Laine L. Low Adherence to Helicobacter pylori Testing in Hospitalized Patients with Bleeding Peptic Ulcer Disease. Helicobacter 2014, 19: 98-104. PMID: 24617668, DOI: 10.1111/hel.12114.Peer-Reviewed Original ResearchConceptsH. pylori testingProportion of patientsIndex hospitalizationHospitalized patientsConsecutive hospitalized patientsPeptic ulcer diseaseHelicobacter pylori testingInitial endoscopyUlcer diseaseSerologic testingSingle centerEndoscopy databaseSociety guidelinesGastric ulcerLow adherencePatientsUlcersMultivariate analysisHelicobacter pyloriHospitalizationDirect testingBiopsyTestingEndoscopyPylori
2002
Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies
Sugg J, Laine L. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. The American Journal Of Gastroenterology 2002, 97: 2992. PMID: 12492181, DOI: 10.1111/j.1572-0241.2002.07116.x.Peer-Reviewed Original ResearchConceptsPersistent H. pyloriErosive esophagitisGERD symptomsH. pyloriSymptomatic GERDPersistent infectionDouble-blind prospective studyDouble-blind prospective trialGastroesophageal reflux disease symptomsCompletion of therapyDuodenal ulcer diseaseGastroesophageal reflux diseaseHelicobacter pylori eradicationHelicobacter pylori therapyWorsening of symptomsEnd of therapyRapid urease testBlind prospective studyPylori eradicationPylori therapyReflux diseaseRegurgitation scoreProspective trialDuodenal ulcerUlcer disease
2000
How to explain outcome differences in dyspepsia studies
Fennerty M, Laine L. How to explain outcome differences in dyspepsia studies. 2000, 421-425. DOI: 10.1007/978-94-011-3927-4_44.ChaptersNon-ulcer dyspepsiaPylori infectionAdequate observation periodPlacebo-controlled trialPeptic ulcer diseaseCause of symptomsH. pylori infectionHelicobacter pylori infectionClinical treatment trialsMajor aetiological factorUlcer diseaseTreatment trialsUpper abdomenAetiological factorsEarly trial resultsStudy populationOutcome differencesEpidemiological studiesH. pyloriDyspepsiaDiscordant resultsTrial resultsObservation periodSerious methodological deficienciesTrials
1999
Review article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment
Schoenfeld, Kimmey, Scheiman, Bjorkman, Laine. Review article: nonsteroidal anti‐inflammatory drug‐associated gastrointestinal complications—guidelines for prevention and treatment. Alimentary Pharmacology & Therapeutics 1999, 13: 1273-1285. PMID: 10540041, DOI: 10.1046/j.1365-2036.1999.00617.x.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsGastrointestinal complicationsPylori infectionSerious gastrointestinal complicationsH. pylori infectionHelicobacter pylori infectionProton pump inhibitorsLowest possible dosagePotential of treatmentNSAID therapyNSAID useAnalgesic therapyCorticosteroid useGastrointestinal bleedingUlcer diseaseAntisecretory agentsPump inhibitorsChronic ingestionPain relieversNSAIDsComplicationsPatientsExact associationPossible dosageRoutine testingPast history
1998
Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials
Laine L, Suchower L, Frantz J, Connors A, Neil G. Twice-daily, 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for Helicobacter pylori eradication in duodenal ulcer disease: results of three multicenter, double-blind, United States trials. The American Journal Of Gastroenterology 1998, 93: ajg1998488. PMID: 9820381, DOI: 10.1111/j.1572-0241.1998.00602.x.Peer-Reviewed Original ResearchConceptsDuodenal ulcer diseaseTriple therapyEradication rateUlcer diseaseH. pylori-infected patientsDaily triple therapyDays of omeprazoleDuodenal ulcer historyProtocol cure ratesProtocol eradication ratesTreat eradication ratesHelicobacter pylori eradicationPylori-infected patientsOAC patientsStudy medicationTreat populationUlcer historyPylori eradicationStudy drugAdverse eventsTwice DailyControlled TrialsDuodenal ulcerCure ratePatientsTwice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials
Laine L, Suchower L, Connors A, Frantz J, Neil G. Twice-daily 10-day triple therapy with omeprazole, amoxicillin, and clarithromycin for H. Pylori eradication in duodenal ulcer disease: Results of 3 multicenter, double-blind, U.S. Trials. Gastroenterology 1998, 114: a193. DOI: 10.1016/s0016-5085(98)80787-7.Peer-Reviewed Original ResearchHelicobacter pylori and peptic ulcer disease
Laine L, Fendrick A. Helicobacter pylori and peptic ulcer disease. Postgraduate Medicine 1998, 103: 231-243. PMID: 9519040, DOI: 10.3810/pgm.1998.03.423.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPeptic ulcer diseaseUlcer diseaseAppropriate antimicrobial therapyPrimary care physiciansCost of careEffective regimensCare physiciansClinical outcomesH pyloriSuccessful treatmentAntimicrobial therapyPatient complianceHelicobacter pyloriImportance of identifyingDiseaseInfectionPyloriTreatmentRegimenRegimensPatientsTherapyPhysiciansCare
1996
Helicobacter pylori and Complicated Ulcer Disease
Laine L. Helicobacter pylori and Complicated Ulcer Disease. The American Journal Of Medicine 1996, 100: 52s-59s. PMID: 8644783, DOI: 10.1016/s0002-9343(96)80229-4.Peer-Reviewed Original ResearchConceptsMaintenance antisecretory therapyComplicated ulcer diseaseUlcer diseaseAntisecretory therapyEradication therapyHelicobacter pyloriH. pylori eradication therapyH. pylori infection statusPylori eradication therapyMajority of patientsPeptic ulcer diseaseEnd of therapyPylori infection statusPrevalence of infectionComplicated ulcersUncomplicated ulcersRecurrent bleedingUlcer healingPatientsTherapyInfection statusUlcersDiseaseBleedingOne-thirdMedical Treatment of Peptic Ulcer Disease: Practice Guidelines
Soll A, Achord J, Bozymski G, Brooks S, Lanza F, Lyon D, Meyer G, Reinus J, Schuster M, Achord J, Ofman J, Glassman P, Laine L, Tytgat G, Walsh J, Graham D, Peterson W. Medical Treatment of Peptic Ulcer Disease: Practice Guidelines. JAMA 1996, 275: 622-629. DOI: 10.1001/jama.1996.03530320046033.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNonsteroidal antiinflammatory drugsRefractory ulcersUlcer patientsPeptic ulcerSuccessful H pylori eradicationConventional maintenance therapyConventional ulcer therapyH pylori eradicationPractice Parameters CommitteeUse of aspirinPeptic ulcer diseaseH pylori infectionAmerican Gastroenterological AssociationMaintenance therapyNSAID usePylori eradicationAntibiotic regimenSymptom reliefAntibiotic therapyUlcer diseaseRecurrence rateUlcer therapyConventional therapyPylori infectionDisease management approach
1988
Prevalence ofCampylobacter pylori and association with antral mucosal histology in subjects with and without upper gastrointestinal symptoms
Pettross C, Appleman M, Cohen H, Valenzuela J, Chandrasoma P, Laine L. Prevalence ofCampylobacter pylori and association with antral mucosal histology in subjects with and without upper gastrointestinal symptoms. Digestive Diseases And Sciences 1988, 33: 649-653. PMID: 3371136, DOI: 10.1007/bf01540425.Peer-Reviewed Original ResearchConceptsUpper gastrointestinal symptomsGastrointestinal symptomsAsymptomatic volunteersNormal endoscopic findingsRoutine endoscopic evaluationPeptic ulcer diseaseYoung asymptomatic adultsAntral inflammationAntral gastritisEndoscopic findingsEndoscopic evaluationMucosal histologyUlcer diseaseAsymptomatic adultsChronic gastritisEndoscopic examinationHistological examinationPatientsVolunteersGastritisMucosaSymptomsExaminationAssociationBiopsy